NRG Oncology CC004 trial: Bupropion does not improve sexual desire for female cancer survivors

By | December 11, 2021
Despite preliminary supporting evidence that the dopaminergic agent bupropion might improve sexual desire for female cancer survivors, the NRG Oncology CC004 clinical trial determined that bupropion did not improve outcomes when compared to a placebo.